Trial Profile
Phase II Study on Letrozole in Patients With Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms deFEND
- Sponsors Novartis
- 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003874).
- 06 Jun 2012 Status changed from suspended to completed as reported by German Clinical Trials Register record.
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2004-003886-34).